Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB017 versus Avonex in pediatric relapsing-remitting multiple sclerosis
2023-505624-56-00Phase 3Authorised
- Sponsor
- Biogen
- Start
- Nov 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Interferons → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of interferon beta and interferon beta-1a in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Biogen. Planned start Nov 2024; status: authorised.
02
Drugs
interferon betainterferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2023-505624-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505624-56-00.